ABBOTT PARK, Ill., May 5 /PRNewswire-FirstCall/ -- Abbott Vascular Devices, a division of Abbott Laboratories (NYSE: ABT), today announced the launch of the next generation Perclose(R) suture-mediated vessel closure system, Perclose ProGlide(TM), featuring polypropylene monofilament suture. The device received approval from the U.S. Food and Drug Administration (FDA) during the first quarter of 2004. Perclose closure devices are designed to close femoral artery puncture sites following diagnostic or interventional procedures. The company will feature Perclose ProGlide with product demonstrations and additional information at the Cardiovascular Revascularization Therapy 2004 symposium being held this week in Washington, D.C. Perclose ProGlide is an important addition to Abbott Vascular Devices -- a leader in vessel closure technologies with one of the broadest portfolios of vessel closure products on the market. With monofilament suture, the ProGlide knot easily advances to the opening in the artery, allowing a single operator to rapidly deliver a pre-tied knot to close the access site in the femoral artery following a catheterization procedure. This secure stitch provides rapid hemostasis, or the cessation of bleeding, and allows patients to recover comfortably by providing the ability to get out of bed in a shorter amount of time. Monofilament suture is also a preferred suture for vascular surgeons due to its high-knotted tensile strength and minimized tissue reaction. "We are pleased to offer Perclose ProGlide with monofilament suture, which expands the Perclose product line to include the same suture material used by vascular surgeons," said Robert B. Hance, president, Abbott Vascular Devices, Abbott Laboratories. "This new generation of our suture-mediated closure system underscores our responsiveness to the needs of clinicians and their patients. We are working to provide the industry's best products for the interventionalist's toolkit." "The incorporation of monofilament suture into the ProGlide device enhances suture handling, making a great device even easier to use," said Mark Dorogy, M.D., an interventional cardiologist at Central Georgia Heart Center, Medical Center of Central Georgia, Macon, Ga. "The security of the suture enables my patients to get out of bed sooner, increasing their satisfaction." Additional features on Perclose ProGlide include the QuickCut(TM) mechanism, which is built into the device to trim the suture after deployment, making it unnecessary to use additional sharps during the procedure. The trimmer facilitates both suture trimming and knot advancement, eliminating a potentially time-consuming step in the vessel closure procedure for many operators. ProGlide also features numbered procedure deployment steps that are printed on the device. In addition, the FDA approved new product labeling for Perclose ProGlide that states there are no reaccess/repuncture restrictions if previous arteriotomy repairs were achieved with a Perclose suture-mediated closure device. This product labeling for Abbott Vascular Devices' Perclose closure products allows physicians to perform repeat procedures using the same access site immediately -- offering increased flexibility to physicians. Abbott Vascular Devices has also begun offering a Continuing Education Unit (CEU) course for nurses and technicians. The course, titled "Building a Pathway for Better Patient Outcomes," focuses on the importance of proper access site management in catheter-based procedures and is available as either a one- or four-credit course. More information is available on this educational course by calling your Abbott Vascular Devices representative or 1-800-222-6883, or by visiting www.abbottvasculardevices.com . About Suture-Mediated Closure American Heart Association research indicates that more than 61 million Americans have cardiovascular disease, and nearly 3 million cardiac catheterizations are conducted in the United States each year. During cardiac catheterization procedures, a long, thin tube (called a catheter) is threaded through a major artery in the leg up to the heart to diagnose or treat certain problems with that organ and its blood supply. Traditionally, doctors have used various methods of applying compression to close the opening to the artery, including direct pressure, sandbags or mechanical clamps. These approaches to vessel closure often result in significant patient discomfort and can require up to several hours to achieve hemostasis. Since the launch of the first Perclose system in 1994, suture-mediated closure technology has enabled physicians to more quickly close the accessed vessel and reduce the bleeding after cardiac catheterization, allowing patients to ambulate safely and improving patient comfort. In addition, a prospective study indicated that use of this technology allows patients to go home sooner, requiring less nursing time for post-procedure monitoring, which may result in cost savings. Abbott Laboratories acquired Perclose, a leader in vessel closure devices, in 1999. About Perclose ProGlide The Perclose ProGlide 6F Suture-Mediated Closure (SMC) System is indicated for the percutaneous delivery of suture for closing the common femoral artery access site of patients who have undergone diagnostic or interventional catheterization procedures using 5F to 8F sheaths. The Perclose ProGlide SMC System should only be used by physicians (or other health care professionals authorized by or under the direction of such physicians) who have been trained in the use of the Perclose ProGlide SMC System, e.g., participation in the Perclose ProGlide SMC System training program or equivalent. About Abbott Vascular Devices Abbott Vascular Devices, a division of Abbott Laboratories headquartered in Redwood City, Calif., is a medical technology pioneer that combines its entrepreneurial spirit with Abbott's pharmaceutical heritage to deliver specialized treatment options that dramatically improve the care of people with vascular disease. Abbott Vascular Devices brings the best of these backgrounds together to develop unique products that meet the specialized needs of vascular disease treatment through three main business units: Vessel Closure Technologies, Coronary Technologies and Endovascular Technologies. About Abbott Laboratories Abbott Laboratories is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 55,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at www.abbott.com .
SOURCE Abbott Laboratories